United States HR 465: Prescription Drug Price Relief Act of 2019

Status: Referred to the Subcommittee on Health. (as of 2019-01-25)

State: United States · Session: 116 · Bill: HR 465

Subjects: Administrative remedies, Asia, Business records, Canada, Civil actions and liability, Competition and antitrust, Department of Health and Human Services, Drug safety, medical device, and laboratory regulation, Europe, France, Germany, Government information and archives, Government studies and investigations, Health care costs and insurance, Health information and medical records, Inflation and prices, Intellectual property, Japan, Licensing and registrations, Manufacturing, Marketing and advertising, Medical research, Prescription drugs, Research and development, United Kingdom

Sponsors: Ro Khanna, Alexandria Ocasio-Cortez, Ayanna Pressley, BARBARA LEE, DANNY K. DAVIS, Debbie Mucarsel-Powell, Debra A. Haaland, ELEANOR HOLMES NORTON, ELIJAH E. CUMMINGS, Grace Meng, Ilhan Omar, JANICE D. SCHAKOWSKY, Jamie Raskin, Joe Neguse, LUCILLE ROYBAL-ALLARD, Mark DeSaulnier, Mark Pocan, PETER A. DEFAZIO, Peter Welch, Pramila Jayapal, ROSA DELAURO, Rashida Tlaib, Tulsi Gabbard

View United States HR 465 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.